Posts

Pharma R&D Spend Drops 3.6% as Pipeline Prioritizations Take Shape

Rare Disease Vouchers Caught in Political Abyss: Recent Updates on Reauthorization Efforts

UK Proposes Raising Payment Scheme for Branded Medicines to Nearly 25% Amid Industry Pushback

Prothena Halts Drug and Plans Major Layoffs After Second Rare Disease Trial Failure